Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors
Status:
Completed
Trial end date:
2013-02-20
Target enrollment:
Participant gender:
Summary
Therapeutic solutions to treat solid tumors that are resistant to conventional treatments are
now limited. Laboratory data in animals (on pediatric tumors such as brain tumors, sarcomas
and neuroblastomas) have shown that the combination of irinotecan (HIF1alpha inhibitor) and
rapamycin (mTOR inhibitor) allowed to block development of blood vessels in the tumor and
could, in some cases, stop its progression. This drug combination has already been tested in
adult patients with refractory tumors and seems to give encouraging results with
stabilization of the tumor. The dose and toxicity of irinotecan and rapamycin are known when
these drugs are administered separately and in a context different from that of refractory
tumors. RAPIRI is a phase I clinical trial whose principal objectives are to determine the
maximum dose at which these two molecules may be administered and to assess the safety of
this new combination of drugs.